EVOLUT Low-Risk Trial data: "We see what we want to see!"
Pradeep NarayanPublished in: Indian journal of thoracic and cardiovascular surgery (2024)
In the 4-year update of the EVOLUT Low-Risk Trial (NCT02701283), the authors highlight a non-significant improvement in the primary endpoint and a statistically significant, yet clinically irrelevant, enhancement in hemodynamics with transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR). Overlooking the concurrent surgical procedures in SAVR patients, mortality rates remain similar at 4 years. Unaddressed is the substantial increase in permanent pacemaker implantations with TAVR and the fate of patients with paravalvular leaks.
Keyphrases
- transcatheter aortic valve replacement
- aortic stenosis
- transcatheter aortic valve implantation
- aortic valve replacement
- aortic valve
- ejection fraction
- phase iii
- end stage renal disease
- study protocol
- clinical trial
- phase ii
- left ventricular
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- coronary artery disease
- peritoneal dialysis
- cardiovascular disease
- open label
- big data
- machine learning
- data analysis
- squamous cell carcinoma
- artificial intelligence
- patient reported outcomes
- atrial fibrillation
- locally advanced